ChronosDx is building a high-performance, low-cost, scalable bioassay technology for drug development and in vitro diagnostics in healthcare.

Our primary application is in early cancer detection, where the technology aims to provide measurements of the low concentrations of target proteins and DNAs present in the early stages. In addition, the bioassay can be used by academic groups, drug and diagnostic development companies and CROs to better test new drugs, validate disease biomarkers and translate biomarker signatures into high-performance tests readily deployable in clinical environments.

To develop our prototype, we are utilising lab facilities at the Royce institute. The state-of-the-art equipment at Royce allows us to fabricate and test the fundamental components of our biosensors. This includes using the Royce cleanroom and characterisation facilities for microfabrication, electrical measurements and surface characterisations.

As a new start-up, Royce's support has been invaluable. In providing us with their facilities, they have acted as a key foundation upon which we can build our technology, which we hope will one day reduce the burden of cancer and give people more time to enjoy their lives. In helping ChronosDx, Royce are enabling a chance for a better future.